FGFR3 and in situ carcinoma: Two main progression pathways have been so far identified in bladder cancer, the Ta pathway characterized by a high frequency of FGFR3 mutation and the carcinoma in situ (Cis) pathway where no or infrequent FGFR3 mutations have been identified.